On May 7, 2003, Staci Dennison presented the following testimony regarding Fiscal Year 2004 Funding for Functional Gastrointestinal and Motility Disorders Research on behalf of IFFGD President, Nancy J. Norton, to the House Appropriations Subcommittee on Labor, Health & Human Services, Education and Related Agencies:

Mr. Chairman and members of the subcommittee, thank you for the opportunity to appear before you today.

My name is Staci Sigman Dennison. I am the Director of Development for the International Foundation for Functional Gastrointestinal Disorders or IFFGD.

In 1991 Nancy Norton founded the International Foundation for Functional Gastrointestinal Disorders (IFFGD), in response to her own experiences as a patient. 12 years later the organization serves hundreds of thousands of people in need each year, providing information and support to patients and physicians. The largest organization of its kind in the world, IFFGD works with consumers, patients, physicians, providers and payers to broaden understanding about fecal incontinence, irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), pediatric disorders and numerous other gastrointestinal disorders. Additionally, it has been her personal vision and goal to see a greater investment in research on functional gastrointestinal and motility disorders.

IFFGD continues to speak about and raise awareness for disorders and diseases that many people are uncomfortable and embarrassed to talk about. The prevalence of fecal incontinence and irritable bowel syndrome, as well as a host of other gastrointestinal disorders affecting both adults and children, is underestimated in the United States. These conditions are truly hidden in our society. Not only are they misunderstood, but the burden of illness and human toll has not been fully recognized.

Given that we have been diligently working for the past twelve years it is an exciting time to lead the IFFGD, not only are we serving more and more people, but we are beginning to be able to privately fund research. Our first research awards were made on April 6, 2003.

Since its establishment the IFFGD has been dedicated to increasing awareness of functional gastrointestinal disorders and motility disorders, among the public, health professionals, and researchers. Last November, we hosted a conference on fecal and urinary incontinence. During the first week of April 2003 we also hosted the Fifth International Symposium on Functional Gastrointestinal Disorders, which was a great success in bringing scientists from across the world together to discuss the current science and opportunities on irritable bowel syndrome and other functional gastrointestinal and motility disorders. The IFFGD has become known for our professional symposia. We consistently bring together a unique group of international multidisciplinary investigators to communicate new knowledge in the field of gastroenterology.

The majority of the diseases and disorders we address have no cure. We have yet to understand the pathophysiology of the underlying conditions. Patients face a life of learning to manage chronic illness that is accompanied by pain and an unrelenting myriad of gastrointestinal symptoms. The costs associated with these diseases are enormous, conservative estimates range between $25 - $30 billion annually. The human toll is not only on the individual but also on the family. Economic costs spill over into the workplace. In essence these diseases reflect lost potential for the individual and society. The IFFGD is a resource and provides hope for hundreds of thousands of people as they try to regain as normal a life as possible.

Fecal Incontinence
Bowel incontinence in particular is often thought of as something that affects us when we are frail and elderly – perhaps something that is part of the aging process.

At least 6.5 million Americans suffer from fecal incontinence. Incontinence is neither part of the aging process nor is it something that affects only the elderly. Incontinence crosses all age groups from children to older adults, but is more common among women and in the elderly of both sexes. Often it is a symptom associated with various neurological diseases and many cancer treatments. Yet, as a society, we rarely hear or talk about the bowel disorders associated with multiple sclerosis, diabetes, colon cancer, uterine cancer, and a host of other diseases, let alone a complication of an episiotomy with vaginal delivery.

Fecal incontinence can be caused by: damage to the anal sphincter muscles; damage to the nerves of the anal sphincter muscles or the rectum; loss of storage capacity in the rectum; diarrhea; or pelvic floor dysfunction. People who have fecal incontinence may feel ashamed, embarrassed, or humiliated. Some don't want to leave the house out of fear they might have an accident in public. Most try to hide the problem as long as possible, so they withdraw from friends and family. The social isolation is unfortunate but may be reduced because treatment can improve bowel control and make incontinence easier to manage.

Irritable Bowel Syndrome (IBS)
Irritable Bowel Syndrome affects approximately 30 million Americans. This chronic disease is characterized by a group of symptoms, which can include abdominal pain or discomfort associated with a change in bowel pattern, such as loose or more frequent bowel movements, diarrhea, and/or constipation. Although the cause of IBS is unknown, we do know that this disease needs a multidisciplinary approach in research and treatment.

Similar to fecal incontinence and depending on severity, IBS can be emotionally and physically debilitating. Because of persistent bowel irregularity, individuals who suffer from this disorder may distance themselves from social events, work, and even may fear leaving their home.

Gastroesophageal Reflux Disease (GERD)
Gastroesophageal reflux disease, or GERD, is a very common disorder affecting both adults and children, which results from the back-flow of acidic stomach contents into the esophagus. GERD is often accompanied by persistent symptoms, such as chronic heartburn and regurgitation of acid. But sometimes there are no apparent symptoms, and the presence of GERD is revealed when complications become evident. Symptoms of GERD vary from person to person. The majority of people with GERD have mild symptoms, with no visible evidence of tissue damage and little risk of developing complications.

Periodic heartburn is a symptom that many people experience. There are several treatment options available for individuals suffering from GERD.

Gastroesophageal reflux (GER) affects as many as one third of all full term infants born in America each year. GER results from an immature upper gastrointestinal motor development. The prevalence of GER is increased in premature infants. Many infants require medical therapy in order for their symptoms to be controlled. Up to 25% of older children and adolescents will have GER or GERD due to lower esophageal sphincter dysfunction. In this population, the natural history of GER is similar to that of adult patients, in whom GER tends to be persistent and may require long-term treatment.

Esophageal Cancer
Approximately 13,000 new cases of esophageal cancer are diagnosed every year in this country. Although the causes of this cancer are unknown, it is thought that this cancer may be more prevalent in individuals who develop Barrett’s esophagus. Diagnosis usually occurs when the disease is in an advanced stage, early screening tools are currently unavailable.

Childhood Defecation Disorders and Diseases
Chronic Intestinal Pseudo-Obstruction (CIP) – About 200 new cases of CIP are diagnosed in American Children each year. Often life threatening, the future for children severely affected with CIP is brightened by the evolving promise of cure with intestinal or multi-organ transplantation.

Hirschsprung's disease – A serious childhood and sometimes life-threatening condition that can cause constipation, occurs only once in every 5,000 American children born each year. Approximately 20% of children with HD will continue to have complications following surgery. These complications include infection and/or fecal incontinence.

Functional constipation – Millions of children (1 in every 10) each year will be diagnosed with functional constipation. In fact, it is the chief complaint of 3% of pediatric outpatient visits and 10-25% of pediatric gastroenterology visits.

Functional Gastrointestinal and Motility Disorders and the National Institutes of Health
The International Foundation for Functional Gastrointestinal Disorders recommends an increase to $29.8 billion or 10% for NIH overall, and a 10% increase for NIDDK, or $1.7 billion. However, we request that this increase for NIH does not come at the expense of other Public Health Service agencies.

We urge the subcommittee to provide the necessary funding for the expansion of the NIDDK’s research program on functional gastrointestinal (FGI) and motility disorders, this increased funding will allow for the growth of new research, a prevalence study and a strategic plan on IBS, and increased public and professional awareness of FGI and motility disorders.

A primary tenant of IFFGD’s mission is to ensure that clinical advancements concerning GI disorders result in improvements in the quality of life of those affected. By working together, this goal will be realized and the suffering and pain millions of people face daily will end.

Thank you.

Nancy J. Norton, IFFGD President
Advisory Board
Board of Directors
Editorial Board Members
Our Mission
Awareness Activities & Accomplishments
Public Education & Awareness
Professional Education & Awareness
Year in Review
Advocacy Activities
Legislative Successes
FGIMD Act (Functional Gastrointestinal and Motility Disorders Research Enhancement Act)
Congressional Testimony
FDA and Other Testimony
Written Comments to FDA June 29, 2015
Oral Comments to FDA May 11, 2015
Comments to FDA July 16th, 2014
Written Comments to Noridian October 24, 2013
Testimony to FDA October 25, 2012
Testimony to FDA September 12, 2012
Testimony to FDA December 13, 2011
Testimony to FDA December 2, 2010
Testimony to FDA April 23, 2002
Comments to FDA November 9, 2000
Testimony to FDA June 27, 2000
Testimony to FDA June 26, 2000
Capital Hill Advocacy Day
IFFGD Research Awards
IFFGD Symposium reports
2013 Professional Symposium
10th Symposium Report
10th Symposium Audio Recordings
More from the 10th Symposium on FGIDs
2011 Professional Symposium
9th Symposium Report
2009 Professional Symposium
2007 Professional Symposium
7th Symposium Report
2005 Professional Symposium
6th Symposium Report
2003 Professional Symposium
5th Symposium Report
2002 Conference - Advancing the Treatment of Incontinence
Corporate Support
Our Research Funding Needs
IFFGD Standards for Collaboration
Industry Council
Code of Ethics
Contact Us
Media Contact

Advocacy Effort

capital hill day s

Involvement in Shaping National Health Care Policy

IFFGD is a voice on Capital Hill working with the digestive health community.

Advocacy Activities, Legislative & Regulatory

Legislative Successes

Congressional Testimony